Counterpoint Mutual Funds LLC Makes New $564,000 Investment in Enovis Corporation $ENOV

Counterpoint Mutual Funds LLC acquired a new stake in Enovis Corporation (NYSE:ENOV) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 24,787 shares of the company’s stock, valued at approximately $564,000.

A number of other institutional investors also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its holdings in shares of Enovis by 11.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock valued at $20,086,000 after purchasing an additional 78,497 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. bought a new position in Enovis in the 4th quarter worth approximately $2,929,000. Invenomic Capital Management LP lifted its holdings in Enovis by 22.7% during the 3rd quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock worth $21,622,000 after buying an additional 131,705 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in Enovis by 36.5% during the 4th quarter. Impax Asset Management Group plc now owns 424,130 shares of the company’s stock worth $11,299,000 after buying an additional 113,500 shares in the last quarter. Finally, Royce & Associates LP boosted its position in Enovis by 14.6% in the 4th quarter. Royce & Associates LP now owns 826,848 shares of the company’s stock valued at $22,027,000 after buying an additional 105,608 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Insider Transactions at Enovis

In related news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 4,200 shares of company stock worth $92,084 in the last quarter. 2.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. William Blair began coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Wells Fargo & Company decreased their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Finally, BTIG Research reissued a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Enovis Stock Performance

Shares of Enovis stock opened at $22.60 on Friday. The firm has a fifty day moving average of $23.23 and a two-hundred day moving average of $23.86. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.14 and a beta of 1.39. Enovis Corporation has a 52 week low of $19.14 and a 52 week high of $36.82.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same period last year, the company earned $0.81 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts predict that Enovis Corporation will post 3.12 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.